Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains...
Six pipeline product profiles were evaluated by current inflammatory bowel disease treaters to assess strengths, weaknesses, and potential prescribing levels...
According to Spherix Global Insights, specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology have little interest in engaging with industry,...
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis)...
Entyvio SC and Remsima SC have experienced noteworthy uptake since their launches in 2020 and are positioned for continued success...
Infliximab and adalimumab biosimilars continue to increase their presence in ulcerative colitis and Crohn’s disease therapy switching, while Entyvio SC...
Spherix Global Insights and Fraser Healthcare are partnering to shed light in this evolving landscape with a new service that...
With both steroid-based and advanced therapies poised for FDA approval in the near term, gastroenterologists’ general satisfaction with current eosinophilic...
Gastroenterologists continue to feel the resonating effects of the COVID-19 pandemic as they work to return operations to pre-pandemic levels,...
A newly published report by Spherix Global Insights includes the responses of 216 gastroenterologists and 1,026 audited patient records in...
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains...
Physician-reported prescribing patterns for Stelara in Crohn’s disease have begun to mirror the favorable impact that the VARSITY clinical trial...
